This video deals with the mechanism of avapritinib in GIST, current outcomes and challenges with PDGFRA D842V mutated GIST presented by Dr. Sameer Rastogi, All India Institute of Medical Sciences, New Delhi, India..
The Gleevec for GIST story continues to remain one of the most successful stories in oncology. What could be better than a drug that works in 85 percent of patients? As great as this story is, there is room for improvement. Half of the patients on Gleevec for metastatic disease will progress in the first two years and 15 percent of patients are resistant to Gleevec right away or within the first six months of treatment. AROG Pharmaceuticals may have an option for a few of those patients.
UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. It's Time to Tell the Stories! Phil Honsey shares his story.
Publicado por Colectivo GIST España - Concluimos el mes dedicado a la concienciación del sarcoma & GIST publicando una actualización del tratamiento para los tumores GIST avanzados.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Stephanie De Jong shares her story.
The New Horizons GIST 2020 Virtual Meeting kicked off on Thursday September 10th at 8am EST. Meeting since 2003, these patient advocates for various cancers split off to a GIST-only meeting several years ago. This year’s meeting, originally planned for Berlin, Germany, was held virtually September 10-12th.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Medicamentos actuales y emergentes “Existen muchas opciones terapéuticas disponibles, pero sigue siendo un desafío hacer coincidir el medicamento correcto con el paciente correcto” Recuerdo en mi memoria ... es junio de 2016, y acabo [...]
LRG’s Senior Director of Research, Pete Knox has summarized the ten key studies relating to GIST that are being presented at the American Society of Clinical Oncology's Annual meeting. ASCO20 is virtual this year.
If you didn't find what you were looking for, try a new search!
